Thank you, Rich. I’d like to begin by providing an update on the credit quality of our portfolio. Overall, the financial health of our portfolio companies remained sound with the trends of continued modest growth and deleveraging continuing through the third quarter. On average, including our stretch first lien senior secured program, the most recently reported organic LTM revenue and EBITDA for our portfolio companies were up around 7% and 11% respectively year-over-year. Measured at fair value, weighted average interest coverage for our portfolio companies was just under 3 times. At the end of the third quarter, the fair value weighted average EBITDA across our portfolio was just over $90 million, and the average leverage through our investment security was just under five times. At September 30, the weighted average investment risk weighting of our total portfolio was 2.0 based on our one to four risk rating scale with one representing the least amount of risk. Measured at fair value, 99.9% of our portfolio was performing at 9/30. On a cost basis, our one investment on non-accrual accounted for 63 bps of the portfolio. Excluding this one legacy asset from 2007 Direct Buy our portfolio is performing very well. On a current cost basis, the weighted average yield on our income producing portfolio was 10.3%. Our average mark on our income producing debt investments as a percentage of par increased to 97.7% of par at 9/30. We believe there is additional net asset value upside above our current [$1.72] per share as our loans that are marked below par due to technical factors are repaid in full. Now I’d like to provide some color on the composition of our comprehensive investment portfolio, which includes Crystal Financial’s portfolio as well as our stressed first lien senior secured loan program. At the end of the third quarter, our $1.6 billion comprehensive investment portfolio included 95 borrowers across 36 industries, with no exposure to direct energy or commodities. The average investment side per borrower is $16.7 million or just over 1% of the comprehensive portfolio, indicating a high degree of diversification. Our single largest loan is 3.2% of the portfolio. Measured at fair value, roughly 96% of our portfolio consisted of senior secured loans, a 3% increase from the June quarter. The remainder of our portfolio was comprised of roughly 2% subordinated debt and 2.5% equity and equity like securities. At September 30, approximately 95% of our income producing portfolio was floating rate on a fair value basis. Before I turn to our investment activity, let me provide a brief update on our strategic initiatives. During the third quarter, SSLP funded $5 million of new stretch senior loans, bringing the total portfolio size to just under $140 million. At the end of September, we had just over $42 million drawn under our new $200 million credit facility on this joint venture. Our annualized yield was 6.4% for the quarter, up from 5.8% in the prior quarter. We continue to expect to achieve a low teens ROE on this vehicle once it is ramped. Also during the third quarter we created a new SSLP II which invested over $65 million in stretch senior loans. We expect to close on our credit facility for this joint venture in the current quarter, and also expect to achieve a low-to-mid teens ROE once the vehicle is fully ramped. At the end of the third quarter, together SSLP and SSLP II had over $200 million of stretch senior secured loans to 11 different borrowers. As of the end of the third quarter, 100% of this portfolio was performing. Now let me turn to life sciences. At the end of the quarter, our life science portfolio totaled approximately $215 million at fair value and consists of first lien senior secured loans across 25 issuers with an average investment size of just over $8.5 million. During the third quarter, our life science team originated approximately $24 million of new senior secured loans. Repayments and amortization totaled just over $37 million during the same period. The average yield at cost, excluding potential exit or success fees as well as any potential warrant gains is running at 12%. The blended IRR on our realized life science investments to date is just under 24%. Now let me give you a quick update on Crystal Financial. At September 30, Crystal had a diversified portfolio consisting of approximately $480 million of funded senior secured loans across 29 borrowers with an average exposure of approximately $16.5 million. During the third quarter, Crystal funded new loans totaling approximately $33 million and had reductions totaling approximately $70 million. All of Crystal’s investments are senior secured loans and over 99% of their portfolio is floating rate. For the third quarter, Crystal paid Solar a cash dividend of $7.9 million, consistent with the prior quarter. Now I would like to turn to our third quarter portfolio activity. During the third quarter, Solar Capital originated approximately $54.5 million consisting predominantly of senior secured floating rate loans across 9 different borrowers. Investments repaid during the quarter totaled $158 million. Starting with originations, we originated a $12 million investment in the first lien loan, Polycom, a manufacturer of voice and video communication equipment. Across the entire solar platform, we invested just under $40 million in this loan, which has a yield of approximately 8.5%. The financing [Indiscernible] of this company by Siris Capital, which has demonstrated expertise in telecommunications, media and technology companies. The EBITDA is approximately $275 million for this company and leverage through our investment is 2.5 times. Additionally our life science team originated a $15 million investment in the first lien term loan of Scynexis. Scynexis is currently developing a novel drug for the treatment of life-threatening invasive fungal infections. Our loan carries a yield in excess of 11%. Now let me touch on our repayments during the third quarter. Our most significant repayment was the repayment of our $48 million investment in the unsecured fixed-rate private note of WireCo. These notes were issued at par – redeemed at par, which resulted in an IRR in excess of 11%. Equally important, the repayment of this investment significantly reduced our exposure to both unsecured and fixed rate assets in our portfolio. Also during the third quarter, our $30 million commitment to Aeropostale, which was sourced through Crystal Financial, was repaid, resulting in an IRR in excess of 40%, albeit only over a 5-month investment period. We were also repaid at par on our $16 million investment in the second lien loan to [Indiscernible]. Rather than rolling our proceeds into the company’s new covenant like dividend recapitalization transaction, we decided to allocate these proceeds to our strategic initiatives, which we believe have more attractive risk reward profiles. The IRR on our investment in [Indiscernible] was over 8.75%. And finally, we repaid on our $18.5 million investment in the second lien loan to Concentra, which was repaid at a premium to par in connection with the company’s refinancing. Similar to [Landesk], we chose not to roll our proceeds into the new second lien transaction. Instead we intend to reinvest the proceeds in [dollar one] risk assets via our proprietary sourcing channels. The realized IRR on this loan to Concentra was just over 11%. As evidenced by our decision not to reinvest proceeds from these investments back into the company’s refinancings, we are focused on originating first lien loans with more attractive pricing and terms through our strategic initiatives. Overall the middle market environment remains competitive given muted sponsor activity year-to-date. In the advanced stages of the current credit cycle, we believe it is imperative to remain highly disciplined in our investment process and exceptionally prudent in deploying our available capital into new investments that meet our strict underwriting criteria. Our strategic initiatives with life science lending and Crystal platforms create attractive growth opportunities, while reducing our reliance on the sponsor-backed community. Longer term, we believe the record amounts of private equity dry powder that has been sitting on the sidelines and the continued retreat of banks from midmarket leverage lending create a very attractive supply demand dynamic for cash flow lending to middle market companies. Our current portfolio leverage is 0.48 relative to our target leverage of 0.65 to 0.75. Including the available capital through our strategic initiatives, Solar has ample capital and the diversified origination engine to continue to grow its portfolio. We have originated on average just over $475 million per year in new investments over the last five years, and our portfolio has grown over 33% since the beginning of last year. Importantly, we have more than doubled our assets in the stretch senior loan programs in 2016 and grew our life science portfolio to over $215 million from a standing start two years ago. We are encouraged by the pickup in sponsor driven M&A activity during this current quarter, and we remain confident in our ability to prudently grow the portfolio in the near term. Thus far during the fourth quarter, we have visibility on only $70 million of repayments and continue to expect portfolio growth in the fourth quarter. Now let me turn the call back over to Michael.